Clinical trials: Prostate Cancer, injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Condition Prostate Cancer
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
This clinical trial studies whether measuring circulating tumor deoxyribonucleic acid (ctDNA) tumor fraction (TF) can be used to help guide the early stopping (discontinuation) of lutetium Lu 177 vipivotide tetraxetan…
- Trial name
- NCT07698535
- Testing
- Lutetium Lu 177 Vipivotide Tetraxetan, Cell-free Circulating Tumor DNA Assay, Computed Tomography
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of Washington
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer
A Phase I Trial of A-CAR032 in Participants With mCRPC
This FTiH, single-arm, open-label, investigator-initiated Phase I trial will evaluate the safety, antitumour activity, CK/pharmacodynamics (PD), biomarkers, immunogenicity, and feasibility of A-CAR032 in adult participants with…
- Trial name
- NCT07344311
- Testing
- dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection
- Where
- 4 sites in China
- Volunteers
- 27 people
- Sponsor
- Shanghai AbelZeta Ltd.
Prostate Cancer
Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of Lutetium Lu 177 JH020002 Injection in adult patients with advanced prostate cancer.
- Trial name
- NCT06139575
- Testing
- Lutetium Lu 177 JH020002 Injection
- Where
- 13 sites in China
- Volunteers
- 90 people
- Sponsor
- Bivision Pharmaceuticals, Inc.
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other…
- Conditions
- Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT03678025
- Testing
- Abiraterone, Bicalutamide, Degarelix
- Where
- 338 sites in United States, Chile and 3 more
- Volunteers
- 1,273 people
- Sponsor
- SWOG Cancer Research Network
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer
This phase II/II trial compares the effect of high dose testosterone followed by darolutamide with the usual care in treating patients with prostate cancer that has spread from where it first started (primary site) to other…
- Trial name
- NCT07852195
- Testing
- Abiraterone Acetate, Biospecimen Collection, Bone Scan
- Volunteers
- 432 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Prostate Cancer
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in subjects with advanced prostate cancer.
- Trial name
- NCT06568094
- Testing
- HRS-5041 tablets, Abiraterone Acetate tablets（II）, Prednisone Acetate tablets
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Prostate Cancer
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer.
- Trial name
- NCT05942001
- Testing
- HRS-5041, Docetaxel injection, Abiraterone acetate tablets
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer
Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-NYM032 in addition to best supportive/best standard of care versus patients treated with…
- Trial name
- NCT07795268
- Testing
- 177Lu-NYM032 injection, Best supportive/best standard of care
- Volunteers
- 600 people
- Sponsor
- Norroy Bioscience Co., LTD
Prostate Cancer
Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Cancer
This is a prospective, open-label, multicenter, Phase I/II exploratory diagnostic imaging study to evaluate the safety, tolerability, radiation dosimetry, pharmacokinetics, biodistribution, imaging characteristics, and…
- Trial name
- COPRA424 (NCT07765940)
- Testing
- [⁶⁴Cu]Cu-RAX301 Injection
- Volunteers
- 52 people
- Sponsor
- RadAlliance Therapeutics, Inc
Prostate Cancer - Recurrent, Prostate Cancer (Diagnosis)
Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU
There would appear to be a strong interest in functional nuclear imaging for assessing the response to focal PaC treatment. Investigator team hypothesise that the diagnostic performance of PSMA PET is noninferior to that of MRI…
- Trial name
- ECETEP (NCT07766122)
- Testing
- Nuclear imaging (PSMA PET) with intravenous injection of a radiotracer one year after treatment (focal therapy)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Toulouse
Castration Resistant Metastatic Prostate Cancer
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment…
- Trial name
- NCT04363164
- Testing
- Testosterone cypionate, Enzalutamide, Testosterone enanthate
- Where
- 6 sites in United States
- Volunteers
- 150 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer (Diagnosis), Transperineal Cryoablation
Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR)
The purpose of this study is to evaluate the feasibility, safety, and potential protective benefit of Barrigel, a hyaluronic acid-based rectal spacer, in patients undergoing prostate cryoablation for localized or recurrent…
- Trial name
- NCT07567027
- Testing
- Barrigel Injectable Gel, Cryoablation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Prostate Cancer
A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer
Primary Objective: To evaluate the safety and tolerability of PET imaging following a single intravenous infusion of [⁶⁸Ga]Ga-ELI421 injection in patients with prostate cancer.
- Trial name
- NCT07689656
- Testing
- [68Ga]Ga-ELI421 injection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Prostate Cancer, Prostate Adenocarcinoma
Effects of Direct Artery Injection on Prostate Cancer Drug Delivery and Tumor Uptake: Imaging-Based Prediction of Treatment Effectiveness
The goal of this clinical trial is to learn whether intra-arterial (IA) administration of 68Ga-PSMA improves tumor uptake and distribution compared with standard intravenous (IV) administration in patients with localized…
- Trial name
- IAPSMA (NCT07656337)
- Testing
- Intraarterial injection of 68Ga-PSMA
- Where
- Lithuania
- Volunteers
- 10 people
- Sponsor
- Lithuanian University of Health Sciences
ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC)
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.
- Conditions
- ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma
- Trial name
- NCT07540572
- Testing
- IDE574, Fulvestrant injection
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- IDEAYA Biosciences
Prostate Cancer
QLF4113 in Participants With Metastatic Prostate Cancer
This is an open-label, dose-escalation and expansion Phase I clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile, immunogenicity, and preliminary antitumor activity of QLF4113 monotherapy in…
- Trial name
- NCT07636707
- Testing
- QLF4113 for injection
- Volunteers
- 140 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Castration-Resistant Prostate Cancer (CRPC)
A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer
An exploratory clinical study evaluating the safety and efficacy of ACT#001 chimeric antigen receptor T-cell (CAR-T cell) local injection in the treatment of castration-resistant prostate cancer.
- Trial name
- NCT07240857
- Testing
- Intraprostatic or localized lesion injection of ACT#001-PSMA CAR-T cells under transrectal ultrasound (TRUS) guidance
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
- Trial name
- NCT05413850
- Testing
- Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only)
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 82 people
- Sponsor
- Blue Earth Therapeutics Ltd
Prostate Cancer
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
The goal of this study is to obtain safety data, establish dose parameters, and effectiveness of treatment for the SpectraCure P18 System with IDOSE®, together with verteporfin for injection (VFI) as photosensitizer, for the…
- Trial name
- NCT06807359
- Testing
- Photodynamic Therapy (PDT), Verteporfin Injection
- Where
- 3 sites in United States, Germany
- Volunteers
- 43 people
- Sponsor
- SpectraCure AB